PARP inhibitor resistance: the underlying mechanisms and clinical implications.

Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. · 2020

Read PARP inhibitor resistance: the underlying mechanisms and clinical implications. by Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7305609.txt.

Description

Li and co-authors review why tumors stop responding to PARP inhibitors, a class of cancer drugs that exploit faulty DNA repair. Their review appeared in Molecular Cancer. Tumors lacking working BRCA1 or BRCA2 genes cannot fix DNA properly, so blocking the PARP enzyme kills them while sparing normal cells, a trick called synthetic lethality.

Resistance, though, is nearly universal. More than 40% of patients with BRCA-deficient tumors never respond, and others lose their response over time. The main escape route is restoring the tumor's homologous recombination repair. Backup protection of DNA replication forks, reversion mutations that fix the original gene faults, epigenetic changes, and drug handling changes also contribute. The authors summarize strategies to overcome resistance or restore sensitivity.

Catalog record

CREATORLi H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE81 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7305609

Browse the full library · About the Tower of Babel